Cargando…
Improved Statistical Signal Detection in Pharmacovigilance by Combining Multiple Strength-of-Evidence Aspects in vigiRank: Retrospective Evaluation against Emerging Safety Signals
BACKGROUND: Detection of unknown risks with marketed medicines is key to securing the optimal care of individual patients and to reducing the societal burden from adverse drug reactions. Large collections of individual case reports remain the primary source of information and require effective analy...
Autores principales: | Caster, Ola, Juhlin, Kristina, Watson, Sarah, Norén, G. Niklas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134478/ https://www.ncbi.nlm.nih.gov/pubmed/25052742 http://dx.doi.org/10.1007/s40264-014-0204-5 |
Ejemplares similares
-
vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real‐world use
por: Caster, Ola, et al.
Publicado: (2017) -
Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase(®)
por: Chandler, Rebecca E., et al.
Publicado: (2016) -
Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project
por: Caster, Ola, et al.
Publicado: (2018) -
Potential safety signals for antibacterial agents from the Brazilian national pharmacovigilance database (Vigimed/VigiFlow)
por: Barbosa, Luiza Hoehl Loureiro Alves, et al.
Publicado: (2022) -
Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase
por: Sandberg, Lovisa, et al.
Publicado: (2020)